BEIGENE LTD-ADR (BGNE) Stock Price, Forecast & Analysis
USA - NASDAQ:BGNE - US07725L1026 - ADR
BGNE Key Statistics, Chart & Performance
The current stock price of BGNE is 184.71 USD. In the past month the price decreased by -10.23%. In the past year, price increased by 11.69%.
BGNE Latest News, Press Relases and Analysis
BGNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About BGNE
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY1-1108 KY
CEO: John V. Oyler
Employees: 10000
Phone: 13459494123
BEIGENE LTD-ADR / BGNE FAQ
What does BGNE do?
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
What is the current price of BGNE stock?
The current stock price of BGNE is 184.71 USD. The price increased by 0.49% in the last trading session.
What is the dividend status of BEIGENE LTD-ADR?
BGNE does not pay a dividend.
What is the ChartMill technical and fundamental rating of BGNE stock?
BGNE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting BGNE stock to perform?
11 analysts have analysed BGNE and the average price target is 185.96 USD. This implies a price increase of 0.68% is expected in the next year compared to the current price of 184.71.
Should I buy BGNE stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BGNE.
BGNE Technical Analysis
BGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGNE. BGNE has a bad profitability rating. Also its financial health evaluation is rather negative.
BGNE Financial Highlights
Over the last trailing twelve months BGNE reported a non-GAAP Earnings per Share(EPS) of -49.45. The EPS decreased by -457.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| Debt/Equity | 0.31 |
BGNE Forecast & Estimates
11 analysts have analysed BGNE and the average price target is 185.96 USD. This implies a price increase of 0.68% is expected in the next year compared to the current price of 184.71.
For the next year, analysts expect an EPS growth of 35.87% and a revenue growth 52.03% for BGNE